Transcode Therapeutics Inc (RNAZ)

$10.56 -0.02 (-0.14%)
Market Cap 8.82M
Revenue (ttm) 0.00
Net Income (ttm) -16.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,500
Avg Vol 20,678
Day's Range N/A - N/A
Shares Out 834,000.00
Stochastic %K 63%
Beta 1.50
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857-837-3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
phantomtrader75
phantomtrader75 Oct. 4 at 8:41 PM
$RNAZ I reported them to SEC and NASDAQ just right before the last split (as well as reporting all affiliated parties) that were complicit. They received a warning and they are on a watch list for purported illegal activities related to improper dilution. That’s why this has been dead in water - they actually have to obey the rules as they are now under heavy scrutiny.
0 · Reply
mbr60
mbr60 Oct. 3 at 9:35 PM
$RNAZ : 🔹 Perspective With the company recently amending its intellectual property agreement with Mass General, the question arises: Could this be a prelude to a strategic partnership in the near future? ✨ Especially since management had previously promised a clinical update at the beginning of September but has yet to deliver it — which may suggest that a bigger step is being prepared behind the scenes. 📌 In the biotech world, adjustments to IP agreements often precede major announcements such as partnerships or strategic funding, making the upcoming period potentially pivotal for the company and its share price.🔥🔥🔥
3 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:40 PM
$RNAZ $XAGE $MLEC $CDIO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:48 AM
$CDT $CNEY $BON $RNAZ |
0 · Reply
rock_it_stocks
rock_it_stocks Oct. 2 at 9:22 PM
$RNAZ A short read of a venture capitalist's take on recent acquisitions of companies with products in Phase 1 (just food for thought): https://www.linkedin.com/posts/johnathanmatlock_why-would-pharma-pay-billions-for-unproven-activity-7374790889254318080-e-Lt .
1 · Reply
BabyDoll1
BabyDoll1 Oct. 2 at 7:13 PM
$RNAZ Have not been here in a while.. have they released any data? Nothing on their “investors” page..
2 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:42 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CNEY $BON $RNAZ $XAGE
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 2 at 2:15 PM
$RNAZ Current Stock Price: $11.00 No options data available.
1 · Reply
Vedran1
Vedran1 Oct. 2 at 4:27 AM
$RNAZ Since the Oncologist / Hematologist presents the poster this is important step forward into medical community about Transcode's basic science research and its recent clinical achievements. An abstract in a form of poster presentation usually preeceds a complete scientific publication in a peer reviewed journal - sometime for a few months, sometime for a year or two. I see this event as a natural progression of Transcodes research and work. This is a slow scientific and clinical process of building a strong base from which we will move on to where we hope to be. It is hard to cut corners here, unless there are extraordinary clinical results early on. https://faculty.mdanderson.org/profiles/siqing_fu.html
1 · Reply
dishenghk
dishenghk Oct. 2 at 3:01 AM
$RNAZ https://oncologypro.esmo.org/content/search?searchText=Phase%201/2%20Clinical%20Study%20of%20a%20First-in-Class%20Antisense%20Oligonucleotide%20(TTX-MC138)%20Therapeutic%20against%20Advanced%20Solid%20Tumors%20of%20Multiple%20Tissue%20Origins From the information on the esmo official website, I found that this might be a brief meeting, not just a poster. "Poster session" vs "Poster Display"
0 · Reply
Latest News on RNAZ
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025, 8:00 AM EDT - 4 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025, 8:05 AM EDT - 5 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025, 5:07 PM EDT - 5 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 5 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025, 9:01 AM EDT - 5 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Apr 21, 2025, 4:37 PM EDT - 5 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 27, 2025, 4:37 PM EDT - 6 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 25, 2025, 6:24 PM EDT - 6 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 23, 2025, 11:11 PM EDT - 6 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Mar 13, 2025, 7:47 AM EDT - 7 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 25, 2025, 4:15 PM EST - 7 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Feb 6, 2025, 8:00 AM EST - 8 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 9 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Jan 7, 2025, 8:00 AM EST - 9 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Dec 18, 2024, 8:00 AM EST - 10 months ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 29, 2024, 4:25 PM EST - 11 months ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 27, 2024, 7:00 AM EST - 11 months ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Nov 5, 2024, 7:00 AM EST - 11 months ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 17, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Sep 5, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Feb 20, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 31, 2024, 4:05 PM EST - 1 year ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 29, 2024, 8:30 AM EST - 1 year ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 22, 2024, 4:45 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 1 year ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 12, 2024, 4:05 PM EST - 1 year ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Jan 4, 2024, 8:05 AM EST - 1 year ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 12, 2023, 8:30 AM EST - 1 year ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 5, 2023, 9:00 AM EST - 1 year ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Dec 4, 2023, 4:10 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 2 years ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Nov 14, 2023, 4:30 PM EST - 2 years ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

TransCode Therapeutics Withdraws Public Offering

Oct 30, 2023, 4:33 PM EDT - 2 years ago

TransCode Therapeutics Withdraws Public Offering

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 27, 2023, 8:00 AM EDT - 2 years ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

TransCode Therapeutics Announces Public Offering of Common Stock

Oct 26, 2023, 4:19 PM EDT - 2 years ago

TransCode Therapeutics Announces Public Offering of Common Stock

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

Oct 26, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Oct 24, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Oct 16, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Sep 28, 2023, 4:02 PM EDT - 2 years ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

phantomtrader75
phantomtrader75 Oct. 4 at 8:41 PM
$RNAZ I reported them to SEC and NASDAQ just right before the last split (as well as reporting all affiliated parties) that were complicit. They received a warning and they are on a watch list for purported illegal activities related to improper dilution. That’s why this has been dead in water - they actually have to obey the rules as they are now under heavy scrutiny.
0 · Reply
mbr60
mbr60 Oct. 3 at 9:35 PM
$RNAZ : 🔹 Perspective With the company recently amending its intellectual property agreement with Mass General, the question arises: Could this be a prelude to a strategic partnership in the near future? ✨ Especially since management had previously promised a clinical update at the beginning of September but has yet to deliver it — which may suggest that a bigger step is being prepared behind the scenes. 📌 In the biotech world, adjustments to IP agreements often precede major announcements such as partnerships or strategic funding, making the upcoming period potentially pivotal for the company and its share price.🔥🔥🔥
3 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:40 PM
$RNAZ $XAGE $MLEC $CDIO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:48 AM
$CDT $CNEY $BON $RNAZ |
0 · Reply
rock_it_stocks
rock_it_stocks Oct. 2 at 9:22 PM
$RNAZ A short read of a venture capitalist's take on recent acquisitions of companies with products in Phase 1 (just food for thought): https://www.linkedin.com/posts/johnathanmatlock_why-would-pharma-pay-billions-for-unproven-activity-7374790889254318080-e-Lt .
1 · Reply
BabyDoll1
BabyDoll1 Oct. 2 at 7:13 PM
$RNAZ Have not been here in a while.. have they released any data? Nothing on their “investors” page..
2 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:42 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CNEY $BON $RNAZ $XAGE
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 2 at 2:15 PM
$RNAZ Current Stock Price: $11.00 No options data available.
1 · Reply
Vedran1
Vedran1 Oct. 2 at 4:27 AM
$RNAZ Since the Oncologist / Hematologist presents the poster this is important step forward into medical community about Transcode's basic science research and its recent clinical achievements. An abstract in a form of poster presentation usually preeceds a complete scientific publication in a peer reviewed journal - sometime for a few months, sometime for a year or two. I see this event as a natural progression of Transcodes research and work. This is a slow scientific and clinical process of building a strong base from which we will move on to where we hope to be. It is hard to cut corners here, unless there are extraordinary clinical results early on. https://faculty.mdanderson.org/profiles/siqing_fu.html
1 · Reply
dishenghk
dishenghk Oct. 2 at 3:01 AM
$RNAZ https://oncologypro.esmo.org/content/search?searchText=Phase%201/2%20Clinical%20Study%20of%20a%20First-in-Class%20Antisense%20Oligonucleotide%20(TTX-MC138)%20Therapeutic%20against%20Advanced%20Solid%20Tumors%20of%20Multiple%20Tissue%20Origins From the information on the esmo official website, I found that this might be a brief meeting, not just a poster. "Poster session" vs "Poster Display"
0 · Reply
wazd
wazd Oct. 1 at 11:02 PM
$RNAZ do not waste your money on this. They will take your money. You will make more money buying weekly dividend stocks than this. Read previous posts…😎
1 · Reply
rock_it_stocks
rock_it_stocks Oct. 1 at 10:21 PM
$RNAZ Transcode to attend the ESMO 2025! Officially! https://ir.transcodetherapeutics.com/events#future
2 · Reply
Scrubinski
Scrubinski Oct. 1 at 1:13 PM
$RNAZ maybe us long investors that have gotten shelled on this stock anyway could pool together $5000 to put TT in a booth at an upcoming conference with some decent handouts and signage. Then TT just has to show up. Might be a worth while investment.
1 · Reply
ioiioiioiioi
ioiioiioiioi Oct. 1 at 5:37 AM
$RNAZ🚨 Found it! $RNAZ core pipeline TTX-MC138 abstract confirmed ✅ 983P: Phase I/II clinical study of a first-in-class antisense oligonucleotide (TTX-MC138) therapeutic against advanced solid tumors Presenter: Siqing Fu, M.D., Ph.D. @ ESMO 2025 (Berlin) Looks like there really will be a presentation. Until then, we just have to wait..! #RNAZ #ESMO2025 #Biotech #GBM https://www.mdanderson.org/research/research-resources/conferences-seminars/md-anderson-at-esmo/esmo-program.html?utm_source=chatgpt.com
2 · Reply
Scrubinski
Scrubinski Oct. 1 at 3:12 AM
$RNAZ I Have heard a few people talk about the ESMO conference in Berlin starting October 17. The timing and venue seems right for an announcement, but I can't find any evidence of TT planning to be there. This is the program https://dam.esmo.org/image/upload/v1758713047/ESMO-Congress-2025-Programme-Book_zjgwfc.pdf don't see anything. Nothing in the booth listing either. Maybe a poster? but usually a poster is just a trifold sitting on table surrounded by hundreds of other posters that may or may not have someone standing there. I guess it's better than nothing, but hard to get much interest in the poster room. Does anybody know anything different?
2 · Reply
soonwee640
soonwee640 Sep. 30 at 8:55 AM
$RNAZ today is the day if the CEO wants to keep his promise. I hope the cohort 1 continue demonstrate stable disease, and other cohorts show no disease progression. Then this is huge for this human trial because metastatic cancer basically in stage IV, survival time is short.
2 · Reply
TradingBeasts
TradingBeasts Sep. 29 at 6:42 PM
$RNAZ 15 soon
0 · Reply
rock_it_stocks
rock_it_stocks Sep. 29 at 5:21 PM
$RNAZ An $8 Billion buyout would be more than $4,000 per share for RNAZ, but that would require our board and management to start thinking and acting like shareholders! As of last reporting, our Board owns a total of 3 shares of common stock between 4 members, so what are the chances that they even care?
1 · Reply
Scrubinski
Scrubinski Sep. 29 at 5:14 PM
$RNAZ I promise to stop complaining if we are acquired for 300 a
0 · Reply
Zeusgodmd
Zeusgodmd Sep. 29 at 4:49 PM
$RNAZ maybe to avoid lawsuits we sell over 300$ per share hopefully our board keeps that in mind
0 · Reply
Vedran1
Vedran1 Sep. 29 at 2:53 PM
$RNAZ MRUS Fair acquisition price? https://www.businesswire.com/news/home/20250929898507/en/MRUS-Stock-Alert-Halper-Sadeh-LLC-Is-Investigating-Whether-the-Sale-of-Merus-N.V.-Is-Fair-to-Shareholders
0 · Reply
Vedran1
Vedran1 Sep. 29 at 2:50 PM
$RNAZ MERUS https://finance.yahoo.com/news/genmab-makes-8-billion-bet-141502866.html
0 · Reply